Review article · 2026 · Open access
Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities
Advanced Drug Delivery Reviews, 236, 115925 · Published 26 June 2026 · DOI 10.1016/j.addr.2026.115925
In brief
“Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities” is a 2026 review article by Suyama Prasansali Mihindukulasooriya and 7 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 20 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Advanced Drug Delivery Reviews.
- Citations
- 20
- Most cited in
- 2026 (20)
- Field-weighted impact
- 6.88
- References
- 110
- Authors
- 8
Abstract
Polyethylene glycol (PEG) is widely used to improve the stability, solubility, and circulation half-life of nanoparticles, proteins, and small-molecule drugs. However, anti-PEG antibodies are increasingly recognized as a clinically relevant variable that can reshape the in vivo fate of PEGylated therapeutics, contributing to accelerated blood clearance, altered biodistribution, loss of efficacy, and, in a subset of individuals, hypersensitivity. This review integrates molecular, formulation, and host determinants of PEG immunogenicity using evidence from preclinical models and human studies. We summarize the prevalence and sources of pre-existing anti-PEG antibodies, including environmental exposure and host genetic associations, and discuss how antibody binding remodels the biomolecular corona, engages Fc- and complement-mediated pathways, and promotes phagocytic uptake that undermines PEG-mediated "stealth". We then evaluate mitigation strategies spanning polymer and lipid design, emerging PEG alternatives, and patient-centered approaches such as baseline antibody profiling and pre-treatment with free PEG in animal models. Finally, we highlight an emerging paradigm that exploits anti-PEG binding for benefit: bispecific anti-PEG antibodies and sequential pre-targeting strategies that convert PEG into a modular handle for active targeting across polymer nanoparticles, liposomes, and mRNA-lipid nanoparticles. Together, this review frames anti-PEG immunity as a central design variable in nanomedicine, linking PEG-mediated stealth, circulation time, targeting efficiency, biomolecular corona formation, and immune recognition. We propose guiding principles for deciding when PEG should be retained and optimized, replaced with alternative stealth materials, managed through patient-level screening or pre-treatment, or deliberately exploited as a modular handle for targeted delivery.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mihindukulasooriya, S. P., Wang, Z., Li, S., Saini, A., Wilson, K., Plebanski, M., Kent, S. J., & Ju, Y. (2026). Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities. Advanced Drug Delivery Reviews, 236, 115925. https://doi.org/10.1016/j.addr.2026.115925
MLA 9
Mihindukulasooriya, Suyama Prasansali, et al. “Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.” Advanced Drug Delivery Reviews, vol. 236, 2026, p. 115925. https://doi.org/10.1016/j.addr.2026.115925.
Chicago
Mihindukulasooriya, Suyama Prasansali, Zhaoran Wang, Shiyao Li, Anamika Saini, Kirsty Wilson, Magdalena Plebanski, Stephen J. Kent, and Yi Ju. 2026. “Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.” Advanced Drug Delivery Reviews 236: 115925. https://doi.org/10.1016/j.addr.2026.115925.
Harvard
Mihindukulasooriya, S. P. et al. (2026) ‘Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities’, Advanced Drug Delivery Reviews, 236, p. 115925. doi:10.1016/j.addr.2026.115925.
IEEE
S. P. Mihindukulasooriya et al., “Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities,” Advanced Drug Delivery Reviews, vol. 236, p. 115925, 2026, doi: 10.1016/j.addr.2026.115925.
BibTeX
@article{mihindukulasooriya2026anti,
title = {{Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities}},
author = {Mihindukulasooriya, Suyama Prasansali and Wang, Zhaoran and Li, Shiyao and Saini, Anamika and Wilson, Kirsty and Plebanski, Magdalena and Kent, Stephen J. and Ju, Yi},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {236},
pages = {115925},
doi = {10.1016/j.addr.2026.115925},
url = {https://doi.org/10.1016/j.addr.2026.115925}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- anti-PEG antibodies
- PEGylation
- stealth nanoparticles
- biomolecular corona
- tissue distribution
- PEG alternatives
- mRNA lipid nanoparticles
- liposomes
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Mihindukulasooriya, S. P., Wang, Z., Li, S., Saini, A., Wilson, K., Plebanski, M., Kent, S. J., & Ju, Y. (2026). Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities. Advanced Drug Delivery Reviews, 236, 115925. https://doi.org/10.1016/j.addr.2026.115925
How many times has this paper been cited?
20 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.
Who wrote this paper?
Suyama Prasansali Mihindukulasooriya, Zhaoran Wang, Shiyao Li, Anamika Saini, Kirsty Wilson, Magdalena Plebanski, Stephen J. Kent, Yi Ju.
What is the DOI of this paper?
10.1016/j.addr.2026.115925, permanently at https://doi.org/10.1016/j.addr.2026.115925. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.